Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth M O'Regan

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
JAMA|September 2, 2004
Do tumors detected by mammography screening have a favorable prognosis?Ruth M O'Regan
The Lancet. Oncology|November 13, 2009
Adjuvant chemotherapy: how much is enough?Ruth M O'Regan
Lancet (London, England)|May 3, 2006
Chemoprevention of breast cancerRuth M O'Regan
Seminars in Oncology|May 5, 2004
New targeted therapies in breast cancerVirginia Kaklamani, Ruth M O'Regan
Clinical Breast Cancer|December 1, 2010
Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathwayRita Nahta, Ruth M O'Regan
Breast Cancer Research and Treatment|April 25, 2012
Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancersRita Nahta, Ruth M O'Regan
CA: a Cancer Journal for Clinicians|May 14, 2005
Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancerRagini Kudachadkar, Ruth M O'Regan
Cancer Treatment and Research|January 20, 2018
Adjuvant Endocrine TherapyRena Shah, Ruth M O'Regan
Biochemical Pharmacology|June 4, 2018
Targeting forkhead box M1 transcription factor in breast cancerRuth M O'Regan, Rita Nahta
Cancer|March 25, 2024
Breast cancer therapy in China: Introducing the Special CollectionXiaojia Wang, Ruth M O'Regan
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
JAMA|September 2, 2004
Do tumors detected by mammography screening have a favorable prognosis?Ruth M O'Regan
The Lancet. Oncology|November 13, 2009
Adjuvant chemotherapy: how much is enough?Ruth M O'Regan
Lancet (London, England)|May 3, 2006
Chemoprevention of breast cancerRuth M O'Regan
Seminars in Oncology|May 5, 2004
New targeted therapies in breast cancerVirginia Kaklamani, Ruth M O'Regan
Clinical Breast Cancer|December 1, 2010
Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathwayRita Nahta, Ruth M O'Regan
Breast Cancer Research and Treatment|April 25, 2012
Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancersRita Nahta, Ruth M O'Regan
CA: a Cancer Journal for Clinicians|May 14, 2005
Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancerRagini Kudachadkar, Ruth M O'Regan
Cancer Treatment and Research|January 20, 2018
Adjuvant Endocrine TherapyRena Shah, Ruth M O'Regan
Biochemical Pharmacology|June 4, 2018
Targeting forkhead box M1 transcription factor in breast cancerRuth M O'Regan, Rita Nahta
Cancer|March 25, 2024
Breast cancer therapy in China: Introducing the Special CollectionXiaojia Wang, Ruth M O'Regan
Pageof 9